Status:
UNKNOWN
Evaluation Of A Mobile Messaging Service In Improving Adherence Of Anti-Seizure Medications
Lead Sponsor:
KEMRI-Wellcome Trust Collaborative Research Program
Collaborating Sponsors:
University of Oxford
African Population and Health Research Center
Conditions:
Epilepsy
Treatment Adherence
Eligibility:
All Genders
Phase:
NA
Brief Summary
This will be a behavioural intervention with no investigational medicinal product. The intervention will be a mobile messaging service that sends short messaging service (SMS) as texts or graphics to...
Detailed Description
Improved outcomes for epilepsy treatment depend on a continuous supply and daily adherence to anti-seizure medications (ASMs). In Kilifi County, the treatment gap which includes both the diagnostic an...
Eligibility Criteria
Inclusion
- Children or adults with a diagnosis of epilepsy ascertained by a clinician at the epilepsy clinic
- Taking anti-seizure medications at the time of the study
- Living within an area defined as the Kilifi Health Demographic Surveillance System, or the Nairobi Urban Health and Demographic Surveillance System at the time of the study or attending the epilepsy clinic in Kilifi or a KAWE-led clinic in Nairobi
- Able to give written informed consent or assent in addition to parental consent (if aged between 13 and 17 years old) to participate in the study either by themselves or in the presence of an independent witness
Exclusion
- Have intellectual disability
- Do not have access to basic mobile phones
- Are currently enrolled in ongoing interventions aimed at improving their health care
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT05321641
Start Date
May 1 2022
End Date
December 1 2024
Last Update
April 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
KEMRI Wellcome Trust Research Programme
Kilifi, Kenya, 80108